The biological activity of peptides is extensive and important, and they can act on the endocrine system, digestive system, cardiovascular system and so on. Although the history of peptides as pharmaceuticals is relatively short, it develops rapidly and has become a hot spot in the market. In the past decades, the number of peptide medications entering the clinical stage has been increasing, such as Semaglutide, Vasopressin, Edotreotide, Thymopentin, etc. With the rapid development of synthetic technology, the development of peptide drugs will make great breakthroughs. The peptide will become a large class of products in the international pharmaceutical market. Its market prospects will be remarkable. KS-V Peptide, as one of the most professional peptide api manufacturers in China, provides high-quality peptide apis for customers to choose from. The following is a peptide api list.
Peptide drugs account for 5% of the global pharmaceutical market, with global sales exceeding $50 billion in 2019. The number of approvals has grown steadily over the past 60 years, with an average growth rate of 7.7% for the global peptide therapeutics market. Insulin analogs accounted for 50% ($25 billion) of peptide drug revenue, followed by the glucagon-like peptide 1 (GLP1) receptor agonist dulaglutide.
Most of the currently approved peptide drugs are agonists, and the most common targeted indications are related to endocrinology, metabolism and oncology.
The structure of peptide molecules is becoming more complex, such as polycyclic peptides, long-chain peptides, alkylation modification, and other difficult peptides. The synthetic technique has been increasingly difficult to meet the demand. In order to improve the activity, structure diversity, and stability of peptide drugs, the synthetic technique has been put forward to higher requirements in the aspects of chemical modification.